Pharma BD Deal Intelligence
Teva acquired Auspex Pharmaceuticals for $3.5B for CNS drug portfolio.
Teva acquired Auspex for $3.5 billion, gaining an innovative biopharmaceutical company specializing in deuterium chemistry to create novel therapies for…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Teva acquired Auspex Pharmaceuticals for $3.5B for CNS drug portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals (this deal) | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
| Teva Pharmaceutical Industries Ltd. / Barr Pharmaceuticals | 2008 | $7.5B | 58 |
← Browse all deals · How we score deals
More: 2015 deals · Teva Pharmaceutical Industries Ltd. deals · Neurology deals